二甲双胍联合SGLT2抑制剂治疗PCOS合并T2DM患者的研究进展
Research Progress of the Combination of Metformin and SGLT2 Inhibitors in the Treatment of PCOS Complicated with T2DM
左金雨 1郑燕2
作者信息
- 1. 重庆医科大学 重庆 400016
- 2. 重庆医科大学 重庆 400016;重庆市垫江县人民医院
- 折叠
摘要
多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者常合并 2 型糖尿病(type 2 diabetes mellitus,T2DM),二者在病因及发病机制上相互联系及影响.二甲双胍是T2DM的基础用药,临床上也用于PCOS,但单用的治疗效果有限,联合其他药物成为治疗的重要选择.钠-葡萄糖协同转运蛋白 2(sodium-glucose cotransporter 2,SGLT-2)抑制剂作为一类有其独特的作用机制的药物,具有良好的治疗效果和广阔的应用范围.现在考虑二甲双胍联用SGLT2 抑制剂治疗PCOS合并T2DM患者,本文对二甲双胍联用SGLT2 抑制剂治疗PCOS合并T2DM患者的研究进展及作用机制进行综述.
Abstract
Polycystic ovary syndrome(PCOS)patients are often complicated by type 2 diabetes mellitus(T2DM),and the two are related and influence each other in etiology and pathogenesis.Metformin is the basic drug for T2DM and is also clinically used for PCOS.However,the therapeutic effect of Metformin alone is limited,and the combination with other drugs has become an important treatment choice.Sodium-glucose cotransporter 2(SGLT2)inhibitors,as a class of drugs with a unique mechanism of action,have a good therapeutic effect and a broad application range.Now,considering metformin combined with SGLT2 inhibitors in the treatment of PCOS combined with T2DM patients,this article reviews the research progress and mechanism of metformin combined with SGLT2 inhibitors in the treatment of PCOS combined with T2DM patients.
关键词
多囊卵巢综合征/2型糖尿病/二甲双胍/钠-葡萄糖协同转运蛋白2抑制剂Key words
PCOS/T2DM/Metformin/SGLT2 inhibitors引用本文复制引用
基金项目
垫江县科技项目(djkjxm2021shmskjcxyw001)
出版年
2024
国家科技期刊平台
NSTL
万方数据